New Delhi, February 02, 2018: In a significant development for Indian patients requiring treatment for structural or congenital heart disease and defects, Admedus Limited (ASX:AHZ) in partnership with Syncronei Medical India Pvt Ltd, and supported by the Australian Trade and Investment Commission (Austrade), is pleased to introduce its ground-breaking and clinically-superior ADAPT® technology in India.
From 30 January 2018, physicians in India will have access to the transformative power and significant patient benefits of ADAPT® engineered tissue and Admedus’ flagship product CardioCel®, a bio-scaffold for the management of congenital and adult structural heart abnormalities.
“In a country with approximately 50 million cardiac patients and 280,000 babies born annually with a Congenital Heart Defect (CHD), the introduction of our disruptive ADAPT® technology is a significant opportunity for India’s physicians to provide life-changing outcomes for their patients,” said Admedus CEO Wayne Paterson.
“CardioCel® has been available in North America and Europe for some time but this is the first time Indian physicians and patients have had access to Admedus’ world-class ADAPT® technology,” he said.
Primarily used in restorative structural heart repair and reconstruction, ADAPT® treated tissue provides unparalleled resistance to calcification, delivering transformative repair with long-term durability that enables native cells to successfully grow and differentiate through the entire repair, without calcification or toxicity.
“Our clinically superior ADAPT® products, invented and manufactured in our state-of-the-art manufacturing facility in Australia, are the only ones to have achieved nine years without calcification or degradation, providing Indian surgeons with a potential lifetime solution for their patients,” Mr Paterson said.
To support the launch of CardioCel® in India, ADAPT® inventor and Admedus Vice President of Cardiovascular Technologies Professor Leon Neethling will deliver a comprehensive series of meetings and presentations with physicians in major health centres across India to demonstrate the product’s clinical applications and benefits.
The official launch activities follow the announcement of 22 November 2017 that Admedus had received regulatory approval to launch our CardioCel® product in the Republic of India, with Syncronei Medical India Pvt Ltd appointed as exclusive commercial partner managing all sales, marketing and distribution. This is an outstanding opportunity for Admedus as it continues to develop as an innovative and bankable business delivering clinically-superior healthcare solutions.
Admedus and Syncronei Medical are looking forward to working closely with Indian clinicians, health officials and key opinion leaders (KOLs) to build productive long-term relationships focused on helping to improve the health outcomes and quality of life for Indian patients with heart disease.
Corporate Comm India(CCI Newswire)
